The Global Intensity-Modulated Radiotherapy Market was valued US$ 2.1 Bn in 2022 and is expected to reach US$ 2.8 Bn by 2032, growing at a CAGR of 5.8% during the forecast period 2023-2032. The versatility of IMRT is another driving force behind its market success. This technology is applicable across various cancer types, including prostate, breast, head and neck, and central nervous system cancers. Its adaptability enables oncologists to tailor treatments to the specific characteristics of each patient's cancer, optimizing therapeutic benefits and minimizing adverse effects. Moreover, the IMRT Market has witnessed a surge in research and development activities, fostering continuous innovation. Ongoing efforts to refine IMRT techniques, enhance treatment planning software, and develop more efficient delivery systems contribute to the market's dynamism. This commitment to advancement underscores the industry's dedication to improving patient outcomes and establishing IMRT as a cornerstone in modern cancer care.